𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination of mood stabilizers with quetiapine for treatment of acute bipolar disorder: an open label study

✍ Scribed by Won-Myong Bahk; Bo-Hyun Yoon; Kyoung-Uk Lee; Jeong-Ho Chae

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
69 KB
Volume
19
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives

The atypical antipsychotics are being increasingly used to control acute manic episodes, and data are emerging to support their mood‐stabilizing and antidepressant properties. This study investigated the short‐term efficacy of quetiapine as an add‐on therapy in the treatment of acute mania.

Method

This study was a 4‐week, open‐label, add‐on, prospective investigation using quetiapine in addition to mood stabilizers. Data on 18 patients fulfilling DSM‐IV diagnostic criteria for bipolar I disorder were analysed. The Young mania rating scale (YMRS), the Hamilton scale for depression (HDRS), the brief psychiatric rating scale (BPRS) and extrapyramidal symptom rating scale (ESRS) were applied at baseline and at weeks 1, 2 and 4. The clinical global impression scale (CGI) was evaluated at baseline and week 4.

Results

The addition of quetiapine produced a statistically significant improvement on the YMRS, HDRS, BPRS and CGI score at week 4 from baseline (p<0.005). Quetiapine was well tolerated, with no subjects discontinuing because of side effects.

Conclusions

The combination of quetiapine was associated with a substantial symptomatic improvement in patients with acute mania. Randomized placebo‐controlled prospective studies are needed. Copyright © 2004 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Duloxetine in the treatment of adolescen
Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study
✍ Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, par

Short-term treatment of post-traumatic s
Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study
✍ Gad Lubin; Abraham Weizman; Mordechai Shmushkevitz; Avi Valevski 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

Eight patients (6 men and 2 women) with chronic post-traumatic stress disorder (PTSD) were treated with naltrexone 100-200 mg/day. Seven patients completed 2 weeks of treatment. A subtle and clinically insignificant improvement was noted in intrusive and hyperarousal symptoms (p < 0.05 for both), bu

Olanzapine monotherapy for acute depress
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial
✍ William V. Bobo; Richard A. Epstein; Richard C. Shelton 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open‐label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery–Asb

The efficacy of reboxetine in the treatm
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
✍ P. N. Dannon; I. Iancu; L. Grunhaus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi

Rapid dose initiation of quetiapine for
Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study
✍ Giuseppina Boidi; Maurizio Ferro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

## Abstract ## Objective Rapid resolution of symptoms is a priority for clinicians treating acute psychosis, and rapid initiation of pharmacotherapy may prove beneficial. This study examined rapid dose initiation of quetiapine in acutely ill patients. ## Methods A 2‐week, multicentre, randomised

Effectiveness of antipsychotic polypharm
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
✍ Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuk 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and ris